In this podcast, 3 members of the Cancer.Net Editorial Board discuss new research presented at the 2023 ASCO Annual Meeting in non-small cell lung cancer, small cell lung cancer, and mesothelioma.
In this podcast, 2 Cancer.Net Associate Editors discuss new research presented at the 2023 ASCO Annual Meeting about preventing melanoma recurrence and reducing cancer disparities.
In this podcast, 3 Cancer.Net Associate Editors discuss new research presented at the 2023 ASCO Annual Meeting in ovarian cancer, uterine cancer, cervical cancer, multiple myeloma, and head and neck cancer.
Read about four studies presented at the 2023 ASCO Breakthrough meeting, covering new ways to use technology to improve cancer screening, as well as a study that showed exercise can help improve sexual health for people with prostate cancer.
In this podcast, 3 Cancer.Net Associate Editors discuss new research presented at the 2023 ASCO Annual Meeting in breast cancer, lymphoma, multiple myeloma, brain tumors, and von Hippel-Lindau syndrome.
Read research from the July 2023 session of the ASCO Plenary Series, which highlights a study evaluating a potential maintenance therapy option for people with advanced or recurrent TP53 wild-type endometrial cancer.
The ASCO Annual Meeting is being held June 2 to 6. A study presented today shows that removing radiation therapy from the treatment plan for an aggressive form of lymphoma does not impact the risk of recurrence or overall survival.
The ASCO Annual Meeting is being held June 2 to 6. Research highlights from the day include using trastuzumab deruxtecan to treat HER2-expressing tumors and using CAR T-cell therapy to slow or stop multiple myeloma.
The ASCO Annual Meeting is being held June 2 to 6. Several notable studies will be presented today. Topics include radiation therapy in rectal cancer, osimertinib for lung cancer, vorasidenib for grade 2 glioma, nivolumab for Hodgkin lymphoma, and mirvetuximab soravtansine for ovarian cancer.
The ASCO Annual Meeting is being held June 2 to 6. A study that will be presented today explores combining immunotherapy and targeted therapy to reduce the risk of death and recurrence for people with advanced ovarian cancer.
